XYZ Robotics Inc. specializes in automating logistics and manufacturing processes through advanced AI-enabled robotic perception and manipulation technology. Founded in 2018 and headquartered in Boston, Massachusetts, with an additional office in Shanghai, China, the company focuses on developing autonomous robotic solutions for tasks such as sorting and picking. Their robotics systems can efficiently organize random warehouse goods into customer order groups, enhancing supply chain management. By leveraging deep learning and sophisticated robotic manipulation algorithms, XYZ Robotics streamlines operations between batch picking and final packaging, ultimately expediting the order fulfillment process.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.
GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.
Almond Fintech is a developer of a cross-border payment platform that facilitates remittances and payments across various providers and borders. The company's platform offers currency exchange services and ensures interoperability between mobile wallets and financial services. This enables individuals and businesses to send and receive money using their existing wallets, streamlining the process of cross-border transactions. By focusing on enhancing mobile financial services, Almond Fintech aims to simplify and improve the user experience for both personal and business financial activities.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.
DeepCure Inc. offers drugs discovery services using artificial intelligence technology. Its products include De-novo Lead Discovery, Artificial Intelligence-driven Lead Optimization, and MoIDB. De-novo Lead Discovery uses artificial intelligence algorithms to analyze drug candidates from virtual library. Artificial Intelligence-driven Lead Optimization identifies optimization steps to improve the development of drugs. MolDB is designed to maximize scale, diversity, and synthesizability of chemical search space. DeepCure Inc. develops new drug through molecular feature extraction, MoIDB, artificial intelligence predictive modeling and feedback loop. The company was founded in 2018 and is based in Boston, Massachusetts.
Robigo specializes in biopesticide development by engineering the plant microbiome to enhance crop health and mitigate diseases. The company focuses on creating precision microbial treatments that not only improve plant vitality but also help recover lost agricultural yields. Utilizing advanced microbial engineering and data science, Robigo's products are designed to be effective while ensuring safety for beneficial microbes, pollinators, humans, and the broader environment. This approach enables farmers to boost their productivity and profitability while promoting sustainable farming practices.
Signet Therapeutics
Seed Round in 2021
Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, utilizing sensors, music, and artificial intelligence to enhance therapeutic outcomes. Founded in 2015 and headquartered in Portland, Maine, the company focuses on patients affected by conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. MedRhythms develops evidence-based interventions aimed at improving walking, speech, cognitive abilities, and overall functional outcomes through the intersection of music and neuroscience. By employing innovative technology and direct brain stimulation techniques, the company aims to provide effective rehabilitation solutions that leverage the therapeutic benefits of music for neurological recovery.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
XYZ Robotics Inc. specializes in automating logistics and manufacturing processes through advanced AI-enabled robotic perception and manipulation technology. Founded in 2018 and headquartered in Boston, Massachusetts, with an additional office in Shanghai, China, the company focuses on developing autonomous robotic solutions for tasks such as sorting and picking. Their robotics systems can efficiently organize random warehouse goods into customer order groups, enhancing supply chain management. By leveraging deep learning and sophisticated robotic manipulation algorithms, XYZ Robotics streamlines operations between batch picking and final packaging, ultimately expediting the order fulfillment process.
Fount Bio is a life science company that applies proprietary advances in glycopolymer research for skin health. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States.
Linus Health, Inc. is a company based in Waltham, Massachusetts, that specializes in brain health monitoring through a digital platform. Founded in 2019, Linus Health develops a mobile application and online platform that collects various digital measurements, including voice, speech, gait, cognition, and eye movement. The platform is designed to facilitate the detection, diagnosis, and treatment of cognitive and mental health conditions. Additionally, it provides clinical decision support and care planning tools, enabling early detection of brain health issues and offering healthcare providers actionable recommendations for patient care. The company's mission is to transform brain health for individuals worldwide through innovative technology.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.
Coin Metrics Inc. is an online publisher specializing in blockchain and cryptocurrency data, offering a range of market and network analytics to various industries. Founded in 2017 and based in Cambridge, Massachusetts, the company provides several key products, including the CM Network Data Pro, which delivers historical crypto network data in a detailed format for institutional clients. Additionally, Coin Metrics offers the CM Market Data Feed, a standardized solution for trade, candle, and order book data from multiple exchanges, and CM Reference Rates, which provides fixed pricing for various assets quoted in U.S. dollars. By focusing on transparent and actionable data, Coin Metrics enables stakeholders to better understand and utilize public crypto networks.
Catalant Technologies, Inc. is a Boston-based software company that specializes in providing solutions for strategy execution to global enterprises. Founded in 2013 and formerly known as HourlyNerd, the company offers a platform that assists organizations in transforming their strategic objectives into actionable plans. Catalant's software enables businesses to align work, access both internal and external resources, collaborate effectively, and measure the value of their efforts, facilitating faster execution of mission-critical projects. The platform connects enterprises with a global network of over 65,000 experts and more than 27,000 boutique firms, providing a streamlined approach to sourcing expertise on demand. By leveraging best-in-class tools for talent management, Catalant helps clients improve efficiency and effectiveness in achieving their strategic goals.
Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, the company aims to address the significant morbidity and mortality associated with sleep apnea, which affects over 20 million Americans. Apnimed's approach targets the neurobiological mechanisms that lead to airway obstruction, offering a simple, orally dosed treatment option. This strategy contrasts with current therapies, which primarily rely on positive pressure devices like CPAP, as well as other less commonly used methods such as mandibular advancement devices and surgical interventions. Apnimed's therapeutics are designed to alleviate both the physiological and symptomatic effects of obstructive sleep apnea, providing a safe and effective solution that addresses the underlying biology of the condition.
Stavvy, Inc. is a financial technology company that specializes in a digital mortgage vendor platform designed to streamline communications and access to vendor data for mortgage banking professionals. The platform offers tools such as Stavvy Connect, which facilitates secure interactions between lenders and their title, settlement, and appraisal vendors, and Stavvy Notarize, which enables real estate professionals to conduct virtual closings and meetings using web conference technology. By eliminating traditional paper processes, Stavvy aims to enhance operational efficiency and compliance while minimizing risks associated with vendor interactions. Founded in 2018 and based in Boston, Massachusetts, the company was formerly known as Stavros Technologies, Inc. before rebranding in August 2020.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
XYZ Robotics Inc. specializes in automating logistics and manufacturing processes through advanced AI-enabled robotic perception and manipulation technology. Founded in 2018 and headquartered in Boston, Massachusetts, with an additional office in Shanghai, China, the company focuses on developing autonomous robotic solutions for tasks such as sorting and picking. Their robotics systems can efficiently organize random warehouse goods into customer order groups, enhancing supply chain management. By leveraging deep learning and sophisticated robotic manipulation algorithms, XYZ Robotics streamlines operations between batch picking and final packaging, ultimately expediting the order fulfillment process.
Vesigen, Inc. is a biotechnology company focused on developing innovative therapeutic products that utilize extracellular vesicle delivery technology to target intracellular sites. Founded in 2020 and based in Cambridge, Massachusetts, the company employs its proprietary ARMMs technology to facilitate the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This approach aims to overcome the challenges associated with intracellular drug delivery, thereby broadening the range of potential druggable targets and enabling the creation of novel treatments for various diseases. Vesigen's mission is to address unmet medical needs through its advanced therapeutic solutions.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.
CairnSurgical is developing innovative patient-specific tools to guide surgical interventions for patients with cancer.
XYZ Robotics Inc. specializes in automating logistics and manufacturing processes through advanced AI-enabled robotic perception and manipulation technology. Founded in 2018 and headquartered in Boston, Massachusetts, with an additional office in Shanghai, China, the company focuses on developing autonomous robotic solutions for tasks such as sorting and picking. Their robotics systems can efficiently organize random warehouse goods into customer order groups, enhancing supply chain management. By leveraging deep learning and sophisticated robotic manipulation algorithms, XYZ Robotics streamlines operations between batch picking and final packaging, ultimately expediting the order fulfillment process.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
CollegeVine is a company based in Cambridge, Massachusetts, founded in 2013, that specializes in providing comprehensive college admissions support. Originally known as Admissions Hero LLC, the company rebranded in August 2016. CollegeVine offers a range of services including mentorship, college application guidance, essay assistance, tutoring, and test preparation. Utilizing data-driven approaches, the company aims to facilitate the college admissions process for students and their families. Additionally, CollegeVine employs advanced artificial intelligence technology to enhance recruitment efforts for colleges and universities, leveraging proprietary data and an extensive network of high school students to streamline assistance in navigating the admissions landscape.
Apic Bio, Inc. is a biotechnology company focused on developing gene therapies for rare and complex neurological and liver diseases. Founded in 2017 and based in Cambridge, Massachusetts, the company specializes in treating conditions such as alpha-1 antitrypsin deficiency. Apic Bio utilizes a gene therapy platform that employs a Dual Function Vector (df-AAV) to simultaneously silence the Z-AAT protein and enhance the M-AAT protein in the liver. This innovative approach aims to address the challenges of genetic diseases through targeted therapies, providing hope for patients with undertreated conditions.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Desora, Inc. is a startup based in Cambridge, Massachusetts, founded by Harvard graduates and faculty in 2016. The company specializes in designing and manufacturing smart cooking appliances, primarily focusing on innovative grilling technology. Its flagship product is a smart barbecue device that can be controlled via a mobile application, allowing users to easily start, stop, and monitor the cooking process. This appliance features a unique design that creates cyclonic smoke spirals to ensure even cooking and eliminate hot spots, making it accessible for novice cooks to achieve exceptional barbecue results. Desora's commitment to combining rigorous science with culinary arts aims to enhance the cooking experience and promote enjoyment in home cooking. The company values diversity and welcomes applications from individuals of all backgrounds.
CollegeVine is a company based in Cambridge, Massachusetts, founded in 2013, that specializes in providing comprehensive college admissions support. Originally known as Admissions Hero LLC, the company rebranded in August 2016. CollegeVine offers a range of services including mentorship, college application guidance, essay assistance, tutoring, and test preparation. Utilizing data-driven approaches, the company aims to facilitate the college admissions process for students and their families. Additionally, CollegeVine employs advanced artificial intelligence technology to enhance recruitment efforts for colleges and universities, leveraging proprietary data and an extensive network of high school students to streamline assistance in navigating the admissions landscape.
Freight Farms, Inc. specializes in the manufacturing of hydroponic crop production units housed in up-cycled shipping containers. Their flagship product, the Leafy Green Machine, allows for the cultivation of various crops, including herbs like mint and basil, as well as a range of lettuces and hearty greens such as kale and cabbage. This innovative farming solution enables high-yield production in any climate and season, making fresh, quality food accessible in areas where traditional agriculture may be challenging. Freight Farms serves a diverse clientele, including business owners, soil farmers, educational institutions, municipalities, and non-profits across the United States, Canada, and Europe. Founded in 2010 and based in Boston, Massachusetts, the company aims to foster local food economies and sustainable food systems through its advanced vertical farming technology.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.
CollegeVine is a company based in Cambridge, Massachusetts, founded in 2013, that specializes in providing comprehensive college admissions support. Originally known as Admissions Hero LLC, the company rebranded in August 2016. CollegeVine offers a range of services including mentorship, college application guidance, essay assistance, tutoring, and test preparation. Utilizing data-driven approaches, the company aims to facilitate the college admissions process for students and their families. Additionally, CollegeVine employs advanced artificial intelligence technology to enhance recruitment efforts for colleges and universities, leveraging proprietary data and an extensive network of high school students to streamline assistance in navigating the admissions landscape.
Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Flyp, Inc. is a telecommunications company based in the United States that aims to enhance the global consumer communications experience. It offers a proprietary platform that allows users to manage multiple phone numbers on a single device while providing high-quality voice and text communications, both in-network and out-of-network. Notably, Flyp serves international customers by offering a unique solution that provides a local US phone number, enabling mobile users to make free calls and send texts to and from any US phone number. This innovative approach allows users to consolidate their mobile communications into one streamlined application, facilitating hassle-free interactions.
Vigeo Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutic agents for treating advanced malignant tumors. Established in 2011, the company is working on a first-in-class drug discovery pipeline aimed at reprogramming the tumor immune microenvironment (TIME). Its lead anti-cancer agent is a peptide fragment derived from the prosaposin protein, which inhibits metastasis and tumor growth by promoting the production of an inhibitory molecule within the tumor microenvironment. Vigeo Therapeutics plans to initiate multiple combination studies to assess the efficacy of its lead product, VT1021, in conjunction with various chemotherapies and anti-PD-1 antibodies, with the goal of improving treatment options for patients with multiple types of cancer.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Synchroneuron Inc. is a biopharmaceutical company focused on developing therapies for tardive dyskinesia and other neuropsychiatric disorders. Its lead candidate, SNC-102, is a sustained-release formulation of acamprosate calcium that aims to enhance pharmacokinetic properties compared to existing formulations. SNC-102 is designed to address tardive dyskinesia by modulating both excitatory and inhibitory neurotransmission in the neural circuits responsible for involuntary movements. The drug is currently undergoing evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as in phase 1 trials for combat-related posttraumatic stress disorder. Founded in 2011 and based in Duxbury, Massachusetts, Synchroneuron was previously known as Eukinetix, Inc.
Freight Farms, Inc. specializes in the manufacturing of hydroponic crop production units housed in up-cycled shipping containers. Their flagship product, the Leafy Green Machine, allows for the cultivation of various crops, including herbs like mint and basil, as well as a range of lettuces and hearty greens such as kale and cabbage. This innovative farming solution enables high-yield production in any climate and season, making fresh, quality food accessible in areas where traditional agriculture may be challenging. Freight Farms serves a diverse clientele, including business owners, soil farmers, educational institutions, municipalities, and non-profits across the United States, Canada, and Europe. Founded in 2010 and based in Boston, Massachusetts, the company aims to foster local food economies and sustainable food systems through its advanced vertical farming technology.
BiddingForGood, Inc. is a charitable e-commerce company that facilitates online auctions for nonprofits, schools, and businesses, enabling them to raise funds for various causes. The platform connects fundraisers with shoppers who are interested in unique and valuable items, generating over $110 million in support of nonprofit organizations and educational institutions. BiddingForGood offers tools such as Auction Manager Pro and Auction Manager Basic, which assist in managing and promoting auctions effectively. The company serves a diverse range of sectors, including K-12 schools, healthcare, higher education, and arts organizations, enhancing their fundraising efforts. With a community of over 220,000 shoppers, BiddingForGood helps businesses engage in philanthropic outreach while accessing new customer bases through its auction events. Established in 2002 and headquartered in Cambridge, Massachusetts, BiddingForGood was previously known as cMarket, Inc. and became a subsidiary of FrontStream Holdings, LLC in 2015.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
Synchroneuron Inc. is a biopharmaceutical company focused on developing therapies for tardive dyskinesia and other neuropsychiatric disorders. Its lead candidate, SNC-102, is a sustained-release formulation of acamprosate calcium that aims to enhance pharmacokinetic properties compared to existing formulations. SNC-102 is designed to address tardive dyskinesia by modulating both excitatory and inhibitory neurotransmission in the neural circuits responsible for involuntary movements. The drug is currently undergoing evaluation in phase 2 trials for tardive dyskinesia and Tourette syndrome, as well as in phase 1 trials for combat-related posttraumatic stress disorder. Founded in 2011 and based in Duxbury, Massachusetts, Synchroneuron was previously known as Eukinetix, Inc.
Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.
Clean Membranes, Inc. produces anti-fouling membranes for various water treatment applications. It offers products for the desalination of seawater and brackish water; purification of surface and well water; municipal and industrial wastewater treatment; pharmaceutical and food industry; oil and gas extraction; industrial and pharmaceutical market; seawater desalination; and producing potable water from brackish water applications. The company was incorporated in 2008 and is based in Lexington, Massachusetts.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
ThingMagic is a leading developer of radio frequency identification (RFID) technology, with broad experience in applying RFID in a wide range of industrial and consumer applications. ThingMagic's customers include some of the world's largest retailers, consumer companies, automotive firms, manufacturers and industrial automation firms. ThingMagic products include fixed and embedded RFID readers and antennas, embedded and OEM RFID technology, and professional services to facilitate the OEM integration of RFID into a wide range of industrial and consumer products.
Serica Technologies, Inc. is a medical device company based in Medford, Massachusetts, specializing in biodegradable, silk-based biomaterial platforms designed for tissue repair. The company develops a range of products, including SeriGel, a bioresorbable silk hydrogel used in plastic and reconstructive surgery, and the SeriFascia surgical scaffold implant, which aids in restoring functional collagen tissue lost due to surgery or aging. Additionally, Serica offers the SeriACL graft for anterior cruciate ligament repair, the SeriCuff scaffold for rotator cuff tendon repair, and the SeriScaffold surgical mesh for the repair of damaged connective tissues. These innovative products serve various applications in orthopedics, sports medicine, and aesthetic and reconstructive plastic surgery. Originally founded as Tissue Regeneration, Inc. in 1998, the company rebranded in 2006 and has since operated as a subsidiary of Allergan Inc.
ThingMagic is a leading developer of radio frequency identification (RFID) technology, with broad experience in applying RFID in a wide range of industrial and consumer applications. ThingMagic's customers include some of the world's largest retailers, consumer companies, automotive firms, manufacturers and industrial automation firms. ThingMagic products include fixed and embedded RFID readers and antennas, embedded and OEM RFID technology, and professional services to facilitate the OEM integration of RFID into a wide range of industrial and consumer products.
BiddingForGood, Inc. is a charitable e-commerce company that facilitates online auctions for nonprofits, schools, and businesses, enabling them to raise funds for various causes. The platform connects fundraisers with shoppers who are interested in unique and valuable items, generating over $110 million in support of nonprofit organizations and educational institutions. BiddingForGood offers tools such as Auction Manager Pro and Auction Manager Basic, which assist in managing and promoting auctions effectively. The company serves a diverse range of sectors, including K-12 schools, healthcare, higher education, and arts organizations, enhancing their fundraising efforts. With a community of over 220,000 shoppers, BiddingForGood helps businesses engage in philanthropic outreach while accessing new customer bases through its auction events. Established in 2002 and headquartered in Cambridge, Massachusetts, BiddingForGood was previously known as cMarket, Inc. and became a subsidiary of FrontStream Holdings, LLC in 2015.
ThingMagic is a leading developer of radio frequency identification (RFID) technology, with broad experience in applying RFID in a wide range of industrial and consumer applications. ThingMagic's customers include some of the world's largest retailers, consumer companies, automotive firms, manufacturers and industrial automation firms. ThingMagic products include fixed and embedded RFID readers and antennas, embedded and OEM RFID technology, and professional services to facilitate the OEM integration of RFID into a wide range of industrial and consumer products.